Pyoderma gangrenosum
Pyoderma gangrenosum je rijetka, upalna kožna bolest u kojoj bolne pustule ili čvorići postaju čirevi koji progresivno rastu. Pyoderma gangrenosum nije zarazan. Liječenje može uključivati kortikosteroide, ciklosporin ili različita monoklonska protutijela. Iako može utjecati na ljude bilo koje dobi, uglavnom pogađa osobe u 40‑im i 50‑im godinama.
☆ AI Dermatology — Free Service
U rezultatima Stiftung Warentest iz Njemačke za 2022., zadovoljstvo potrošača s ModelDermom bilo je samo malo niže nego s plaćenim konzultacijama o telemedicini.
U rezultatima Stiftung Warentest iz Njemačke za 2022., zadovoljstvo potrošača s ModelDermom bilo je samo malo niže nego s plaćenim konzultacijama o telemedicini.
Na nozi osobe s ulceroznim kolitisom.
relevance score : -100.0%
ReferencesPyoderma gangrenosum je rijetko stanje kože koje uzrokuje bolne čireve s crvenim ili ljubičastim rubovima. Klasificira se kao upalna bolest i dio je skupine koja se naziva neutrofilne dermatoze. Uzrok pyoderma gangrenosum je složen i uključuje probleme s urođenim i adaptivnim imunitetom kod osoba koje su genetski sklone. Nedavno su istraživači usredotočili pažnju na folikulu dlake kao potencijalnu početnu točku bolesti.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum je rijetko stanje kože koje uzrokuje izrazito bolne čireve. Iako njegov uzrok nije u potpunosti poznat, znamo da uključuje povećanu aktivnost određenih imunoloških stanica. Liječenje bolesti još uvijek nije jednostavno. Postoje razni lijekovi koji suzbijaju imunološki sustav ili modificiraju njegovu aktivnost, a uz to se usredotočujemo i na liječenje rana te upravljanje boli. Kortikosteroidi i ciklosporin često su prvi izbor u liječenju, ali u posljednje vrijeme postoji sve više istraživanja o upotrebi bioloških terapija, poput inhibitora TNF‑α. Ovi biološki lijekovi sve više pokazuju prednosti, posebno kod pacijenata s drugim upalnim stanjima, i koriste se i ranije u tijeku bolesti.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
